文献速递类风湿关节炎脊柱关节炎

JAK1:家族中的第一位?炎症中的第一位?

JAK1: Number one in the family; number one in inflammation?
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本文综述JAK-STAT通路中JAK1在炎症性疾病信号传导中的核心地位。JAK1参与γc受体细胞因子、IL-6及IFN的信号传导,JAK1选择性抑制剂在类风湿关节炎中有效,并在中轴型脊柱关节炎中显示前景。JAK1在滑膜炎症和骨稳态中的作用被讨论,但JAK1相对于其他激酶的贡献尚不明确。

要点

  • JAK1介导γc受体细胞因子、IL-6及IFN的信号传导,其选择性抑制可能与非选择性JAK抑制剂疗效相当。
  • JAK1选择性药物在类风湿关节炎中有效,并在中轴型脊柱关节炎中显示前景。
  • JAK抑制剂对骨侵蚀的有益作用有临床前和临床数据支持,但对中轴型脊柱关节炎新骨形成的影响需进一步研究。

核心结论

  • JAK1在炎症相关细胞因子信号传导中处于关键位置,JAK1选择性抑制剂可能与非选择性JAK抑制剂疗效相当且避免JAK2或JAK3阻断的不良后果。

研究设计与样本

  • 本文为综述,未报告系统检索范围或样本量。

主要发现

  • JAK1参与γc受体细胞因子(IL-2、IL-4、IL-7、IL-9、IL-15和IL-21)、包括IL-6在内的促炎细胞因子以及IFN的信号传导。
  • 非选择性JAK抑制剂和新型JAK1选择性药物在RA中的疗效支持JAK1在其发病机制中的作用。
  • JAK1选择性药物在中轴型脊柱关节炎中显示前景,可能靶向影响TNF和IL-17A等不使用JAK的细胞因子的额外调控通路。
  • 证据支持JAK1在滑膜成纤维细胞、巨噬细胞和内皮细胞中IL-6和制瘤素M信号传导中的主导地位,并间接影响TNF。
  • 骨稳态依赖JAK1信号传导的细胞因子促进成骨细胞和T细胞中RANKL表达,从而促进破骨细胞生成。

关键数值与推荐

  • JAK1选择性抑制剂在RA中的疗效支持JAK1在发病机制中的作用;JAK1在骨稳态中的贡献相对于其他激酶尚不明确。

临床怎么用

  • JAK1选择性抑制可能为RA及中轴型脊柱关节炎提供治疗选择,但需权衡JAK1抑制对骨稳态的潜在影响。

局限性

  • JAK1相对于其他激酶的贡献不明确;JAK抑制剂对中轴型脊柱关节炎新骨形成的影响需额外研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several cytokines involved in inflammatory pathologies signal via the Janus kinase-signal transducer and activator of transcription pathway. Four JAKs are known: JAK1, JAK2, JAK3 and TYK2. The specific activation of JAKs and STATs determines the biological effects of each cytokine. JAK1 is involved in the signalling of 'γc' receptor cytokines (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21), pro-inflammatory cytokines including IL-6, as well as IFN. The critical position of JAK1 downstream of these cytokines suggests that JAK1-selective inhibitors are comparable to non-selective ones, without the unwanted consequences of JAK2- or JAK3-blockade. JAK inhibition has led to a better understanding of the biology of synovial inflammation and bone homeostasis. Moreover, the efficacy of non-selective JAK inhibitors and novel JAK1-selective drugs in RA supports a role for JAK1 in its pathogenesis. JAK1-selective drugs are also showing promise in axial spondyloarthritis, suggesting that they may target additional regulatory pathways that impact cytokines such as TNF and IL-17A, which do not use JAKs. Additionally, evidence now supports a JAK1 predominance in the signalling of IL-6 and oncostatin M, and indirectly, of TNF in synovial fibroblasts, macrophages and endothelial cells. Notably, bone homeostasis is also dependent on cytokines relying on JAK1 signalling to promote receptor activator of NF-κB ligand expression in osteoblasts and T cells, contributing to osteoclastogenesis. Here, the contribution of JAK1 over other kinases is unclear. While beneficial effects of JAK inhibitors on bone erosion are supported by preclinical and clinical data, effects on new bone formation in axial spondyloarthritis requires additional study.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Spinelli FR, Colbert RA, Gadina M, et al. JAK1: Number one in the family; number one in inflammation? Rheumatology (Oxford). 2021. PMID: 33950229. doi:10.1093/rheumatology/keab024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。